NORCROSS,Immucor, a provider of technology for the blood transfusion industry, is planning a 3-for-2 stock split on June 30.

The company currently has 20 million shares of common stock outstanding. It is the firm’s sixth stock split since 1985, including a 3-for-2 split last year.

Immucor (Nasdaq: BLUD) recently won approval from the FDA for a new device called Galileo.